צמיחת רווחי EPS רבעונית Applied Therapeutics Inc. (APLT)
Applied Therapeutics (APLT) intellectual property in the US minimizes external risks, while the value of 72.70 aligns with the current metric. The quarterly EPS trend captures the growth rate of earnings per share. A closed system of aldose reductase inhibitors forms the business foundation, while financial potential is based on high-cost orphan drugs for the treatment of galactosemia purchased by insurance funds.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_APLT_-_Applied-Therapeutics_-_Year-over-year-earnings-per-share-growth-for-the-last-12-months "APLT: צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים appliedtherapeutics.com 04.07.2022 - 16.02.2026 | 👁️GURU.Markets👁️")
Applied Therapeutics Inc. (APLT) - פילוחי מדדים ודוחות פיננסיים
To assess the issuer's financial stability, the trend of net income per share is utilized, where quarterly growth measures the pace of business capitalization and cost management efficiency. By analyzing the actual quarterly EPS growth, an investor can see how the monetization of the proprietary aldose reductase inhibitor platform of Applied Therapeutics (APLT) transforms into real income, cementing the company's dominance in the rare metabolic pathology treatment segment.
